Imelda Juniarsih

Maxwellia is a pioneering British start-up pharma company building a pipeline of consumer healthcare brands that will help people look after themselves. We do this by converting prescription only medicines to versions that people can buy in a pharmacy. This process is known as switching (previous well-known examples of switches are Nurofen, Canesten and Viagra Connect). Switching is a rigorous regulatory process facilitating the safe supply of medicines under the supervision of a pharmacist. We are the world’s only company with the commercial, medical, and scientific, innovation and regulatory acumen, switch expertise and dynamism, dedicated to bringing prescription medicines to life as brands that can be bought from the local pharmacy. In the UK £2bn is spent every year on 18 million GP consultations for conditions that people can manage for themselves. That’s a lot of time that hard-pressed doctors could be spending on more serious conditions. Pharmacists are highly trained healthcare professionals and their expertise is extensive but currently the products they can sell to their customers are limited to traditional categories such as coughs, colds, pain, skin and digestive remedies, this limits their ability to play a bigger role, within primary care, and help ease the burden on doctors and the NHS. Our ambition is to widen access to a range of medicines and broaden the role of pharmacist so that people can access the advice and medicines they need to manage their health without the need for a GP appointment and prescription, thereby reducing the load on an over-stretched NHS. We’re working across a wide range of therapy areas building our pipeline to widen access to a range of widely used and effective medicines delivering breakthrough products into the hands of the people that need them by making them convenient and easy to access in their local pharmacy Innovation is our everyday, helping people get their lives back is our mantra.

Deep Branch developed a patented technology platform that use carbon dioxide and hydrogen as feedstocks for fermentation, instead of sugar. The company was acquired by Aerbio in 2024.

Nexus Labs is an innovative medical education start-up that specialises in the production of industry-leading educational videos and learning platforms. Our team, led by surgeon Dr Glyn Estebanez, prides itself in using cutting-edge digital technology, CGI animations and real-life footage to enhance traditional learning experiences and not just replicate them. We work with experts in the surgical field to ensure all of our educational content is of the highest accuracy and that difficult concepts can be broken down, simplifying the learning experience. We aim to reduce the gap between medical knowledge and application, and ultimately improve patient care around the world.

Selentus develops innovative haemostatic technologies for better surgical outcomes. Selentus is developing a pipeline of products based on its unique technology platform that offer high performance, low cost manufacture and avoid the use of blood-derived materials. Selentus lead product, TenaTac®, was approved for sale in Europe in September 2019.

Maxwellia is a pioneering British start-up pharma company building a pipeline of consumer healthcare brands that will help people look after themselves. We do this by converting prescription only medicines to versions that people can buy in a pharmacy. This process is known as switching (previous well-known examples of switches are Nurofen, Canesten and Viagra Connect). Switching is a rigorous regulatory process facilitating the safe supply of medicines under the supervision of a pharmacist. We are the world’s only company with the commercial, medical, and scientific, innovation and regulatory acumen, switch expertise and dynamism, dedicated to bringing prescription medicines to life as brands that can be bought from the local pharmacy. In the UK £2bn is spent every year on 18 million GP consultations for conditions that people can manage for themselves. That’s a lot of time that hard-pressed doctors could be spending on more serious conditions. Pharmacists are highly trained healthcare professionals and their expertise is extensive but currently the products they can sell to their customers are limited to traditional categories such as coughs, colds, pain, skin and digestive remedies, this limits their ability to play a bigger role, within primary care, and help ease the burden on doctors and the NHS. Our ambition is to widen access to a range of medicines and broaden the role of pharmacist so that people can access the advice and medicines they need to manage their health without the need for a GP appointment and prescription, thereby reducing the load on an over-stretched NHS. We’re working across a wide range of therapy areas building our pipeline to widen access to a range of widely used and effective medicines delivering breakthrough products into the hands of the people that need them by making them convenient and easy to access in their local pharmacy Innovation is our everyday, helping people get their lives back is our mantra.

Deep Branch developed a patented technology platform that use carbon dioxide and hydrogen as feedstocks for fermentation, instead of sugar. The company was acquired by Aerbio in 2024.

Nexus Labs is an innovative medical education start-up that specialises in the production of industry-leading educational videos and learning platforms. Our team, led by surgeon Dr Glyn Estebanez, prides itself in using cutting-edge digital technology, CGI animations and real-life footage to enhance traditional learning experiences and not just replicate them. We work with experts in the surgical field to ensure all of our educational content is of the highest accuracy and that difficult concepts can be broken down, simplifying the learning experience. We aim to reduce the gap between medical knowledge and application, and ultimately improve patient care around the world.

Pioneer Group connects your life sciences company to lab space, offices and business accelerator programmes to help you launch, grow and scale. Our ten science campuses are located nationwide and include: - BioCity Nottingham - BioCity Glasgow - Wilton Centre - Hexagon Tower, Manchester - Cardiff Edge - Edinburgh Technopole - MediCity Nottingham - Kent Science Park - Colworth Science Park - Cherrywood, Dublin